CervoMed and Others See Significant Stock Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2026
0mins
Source: NASDAQ.COM
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERT
Wall Street analysts forecast CERT stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 7.130
Low
9.00
Averages
12.11
High
16.00
Current: 7.130
Low
9.00
Averages
12.11
High
16.00
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions, providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,600 biopharmaceutical companies, academic institutions and biotech companies across 70 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MindWalk Files European Patent for Biological Data Architecture Underpinning AI Drug Discovery
- Patent Application Background: MindWalk Holdings Corp. filed European patent application EP26187897.9 in June 2026 to protect high-dimensional biological data structures underpinning its HYFT® technology, reflecting the company's focus on the biological data layer in response to the increasing interchangeability of AI models.
- Architectural Advantage: The patent application emphasizes the importance of biological context, with CEO Jennifer Bath, Ph.D., arguing that future competitive advantages will stem from structured biological data rather than individual AI models, aiming to enhance efficiency in drug discovery.
- Commercial Application Potential: MindWalk's ReefIQ™ and LensAI™ platforms are establishing contractual relationships with life sciences customers, and the patent protection will support the future development of these platforms, with AI spending in drug discovery projected to grow from $5 billion in 2026 to over $8 billion by 2030.
- Preclinical Results Showcase: MindWalk has reported preliminary results in preclinical studies for dengue and influenza, where HYFT® technology helped identify biological patterns; although further research is needed to validate clinical translation potential, it demonstrates the promising application of this technology in drug discovery.
See More
MindWalk Files European Patent for Biological Data Architecture Underpinning AI Drug Discovery
- Patent Application Overview: MindWalk Holdings Corp. filed European patent application EP26187897.9 in June 2026 to protect high-dimensional biological data structures underpinning its HYFT® technology, which is expected to enhance its competitive edge in the biopharmaceutical sector.
- Market Potential Analysis: According to third-party estimates, spending on AI in drug discovery is projected to grow from approximately $5 billion in 2026 to over $8 billion by 2030, and MindWalk's patent application aims to secure a favorable position in this rapidly expanding market.
- Technological Architecture Innovation: The patent application builds on MindWalk's foundational HYFT patent, aiming to protect a unique computational layer that allows structured representation of biological data to support AI model reasoning and comparison, thereby improving drug discovery efficiency.
- Industry Context and Competitive Advantage: In a landscape where AI models are becoming increasingly interchangeable, MindWalk emphasizes that the protection of its biological data layer will be crucial for maintaining a lasting competitive advantage, helping the company stand out in the fast-evolving life sciences AI field.
See More
Certara Under Investigation for Securities Fraud Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in Q1 2026, indicating weak performance from Tier 1 customers in MIDD services, which could hinder future revenue growth.
- Exit from Regulatory Business: The company announced its exit from the regulatory segment of its services, a strategic shift that may further impact its market competitiveness and client base, particularly against the backdrop of mixed service performance.
- Executive Departure Impact: CFO John Gallagher's announcement of his resignation effective July 14, 2026, led to an 8.13% drop in Certara's stock price to $5.54 on June 18, reflecting market concerns over leadership changes and their implications for the company's stability.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Certara and its executives have engaged in securities fraud or other unlawful business practices, which could expose the company to legal risks and potential financial liabilities, exacerbating investor anxiety.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, raising concerns among investors about potential future revenue growth challenges.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', indicating challenges in maintaining customer relationships and market competitiveness, which could impact its market share.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that may further affect the company's revenue structure and business diversity, increasing uncertainty regarding its future growth prospects.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price plummeted from $6.31 to $5.13 per share, a decline of approximately 19%, reflecting market concerns over the company's financial health and potentially diminishing investor confidence.
See More
Investigation into Certara Investor Losses Announced
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in Q1 2026, indicating weak performance among Tier 1 customers that could hinder future revenue growth.
- Execution Challenges: The company acknowledged execution and go-to-market challenges in its services business, with inconsistencies between software and services performance, reflecting difficulties in business integration and responsiveness to customer demands, which may erode investor confidence.
- Executive Transition: On June 17, 2026, Certara announced CFO John Gallagher's resignation effective July 14, 2026, with Faiz Mohammed stepping in as Interim CFO, raising concerns about management stability that could further impact stock prices.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Certara complied with federal securities laws, and if investors suffered losses from holding Certara stock, they may seek compensation through legal channels, potentially damaging the company's reputation and shareholder trust.
See More
Certara CFO John Gallagher to Resign in 2026
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating potential instability at the executive level, which may impact investor confidence.
- Interim Appointment: Faiz Mohammed will serve as interim CFO; currently the Senior VP of Finance, he brings over 25 years of finance and accounting experience, expected to provide transitional support during this period.
- Stock Price Fluctuation: Certara shares closed at $6.03, down 0.33%, and traded at $5.88 in the overnight market, reflecting a 2.49% decline, indicating market concerns regarding the executive change.
- Market Reaction: The resignation news may prompt investors to reassess Certara's future financial performance, potentially putting pressure on the stock price in the short term and affecting the company's competitiveness in the biotech sector.
See More
MindWalk Files European Patent for Biological Data Architecture Underpinning AI Drug Discovery
- Patent Application Background: MindWalk Holdings Corp. filed European patent application EP26187897.9 in June 2026 to protect high-dimensional biological data structures underpinning its HYFT® technology, reflecting the company's focus on the biological data layer in response to the increasing interchangeability of AI models.
- Architectural Advantage: The patent application emphasizes the importance of biological context, with CEO Jennifer Bath, Ph.D., arguing that future competitive advantages will stem from structured biological data rather than individual AI models, aiming to enhance efficiency in drug discovery.
- Commercial Application Potential: MindWalk's ReefIQ™ and LensAI™ platforms are establishing contractual relationships with life sciences customers, and the patent protection will support the future development of these platforms, with AI spending in drug discovery projected to grow from $5 billion in 2026 to over $8 billion by 2030.
- Preclinical Results Showcase: MindWalk has reported preliminary results in preclinical studies for dengue and influenza, where HYFT® technology helped identify biological patterns; although further research is needed to validate clinical translation potential, it demonstrates the promising application of this technology in drug discovery.
See More
MindWalk Files European Patent for Biological Data Architecture Underpinning AI Drug Discovery
- Patent Application Overview: MindWalk Holdings Corp. filed European patent application EP26187897.9 in June 2026 to protect high-dimensional biological data structures underpinning its HYFT® technology, which is expected to enhance its competitive edge in the biopharmaceutical sector.
- Market Potential Analysis: According to third-party estimates, spending on AI in drug discovery is projected to grow from approximately $5 billion in 2026 to over $8 billion by 2030, and MindWalk's patent application aims to secure a favorable position in this rapidly expanding market.
- Technological Architecture Innovation: The patent application builds on MindWalk's foundational HYFT patent, aiming to protect a unique computational layer that allows structured representation of biological data to support AI model reasoning and comparison, thereby improving drug discovery efficiency.
- Industry Context and Competitive Advantage: In a landscape where AI models are becoming increasingly interchangeable, MindWalk emphasizes that the protection of its biological data layer will be crucial for maintaining a lasting competitive advantage, helping the company stand out in the fast-evolving life sciences AI field.
See More
Certara Under Investigation for Securities Fraud Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in Q1 2026, indicating weak performance from Tier 1 customers in MIDD services, which could hinder future revenue growth.
- Exit from Regulatory Business: The company announced its exit from the regulatory segment of its services, a strategic shift that may further impact its market competitiveness and client base, particularly against the backdrop of mixed service performance.
- Executive Departure Impact: CFO John Gallagher's announcement of his resignation effective July 14, 2026, led to an 8.13% drop in Certara's stock price to $5.54 on June 18, reflecting market concerns over leadership changes and their implications for the company's stability.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Certara and its executives have engaged in securities fraud or other unlawful business practices, which could expose the company to legal risks and potential financial liabilities, exacerbating investor anxiety.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, raising concerns among investors about potential future revenue growth challenges.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', indicating challenges in maintaining customer relationships and market competitiveness, which could impact its market share.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that may further affect the company's revenue structure and business diversity, increasing uncertainty regarding its future growth prospects.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price plummeted from $6.31 to $5.13 per share, a decline of approximately 19%, reflecting market concerns over the company's financial health and potentially diminishing investor confidence.
See More
Investigation into Certara Investor Losses Announced
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in Q1 2026, indicating weak performance among Tier 1 customers that could hinder future revenue growth.
- Execution Challenges: The company acknowledged execution and go-to-market challenges in its services business, with inconsistencies between software and services performance, reflecting difficulties in business integration and responsiveness to customer demands, which may erode investor confidence.
- Executive Transition: On June 17, 2026, Certara announced CFO John Gallagher's resignation effective July 14, 2026, with Faiz Mohammed stepping in as Interim CFO, raising concerns about management stability that could further impact stock prices.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Certara complied with federal securities laws, and if investors suffered losses from holding Certara stock, they may seek compensation through legal channels, potentially damaging the company's reputation and shareholder trust.
See More
Certara CFO John Gallagher to Resign in 2026
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating potential instability at the executive level, which may impact investor confidence.
- Interim Appointment: Faiz Mohammed will serve as interim CFO; currently the Senior VP of Finance, he brings over 25 years of finance and accounting experience, expected to provide transitional support during this period.
- Stock Price Fluctuation: Certara shares closed at $6.03, down 0.33%, and traded at $5.88 in the overnight market, reflecting a 2.49% decline, indicating market concerns regarding the executive change.
- Market Reaction: The resignation news may prompt investors to reassess Certara's future financial performance, potentially putting pressure on the stock price in the short term and affecting the company's competitiveness in the biotech sector.
See More
